NGHIÊN CỨU ĐIỀU TRỊ BỆNH HẮC VÕNG MẠC TRUNG TÂM THANH DỊCH BẰNG DUNG DỊCH NHỎ MẮT BRINZOLAMIDE 1%

Abstract

Purpose: Evaluate the effectiveness of topical brinzolamide in the treatment of central serous chorioretinopathy. Methods: Prospective, randomized, controlled intervention study of 58 eyes (54 patients) diagnosed with serous central chorioretinopathy at Vietnamese National Institute of Ophthalmology from November 2022 to August 2023. Treated cases (n = 35) had received topical brinzolamide 1% two times a day for 3 months while controls (n=23) were observed without active intervention. Results: At the main study end point of 3 months, treated patients who received topical brinzolamide 1% had significantly faster resolution of subretinal fluid with a mean central macular thickness in central macular thickness (from 442.11 ± 122.36 µm to 264.02 ± 69.28 µm) compared to observed controls  (from 483.32 ± 129.69 µm to 365.37 ± 108.91 µm) (p=0.021). Treated cases had greater reduction of subretinal fluid height (from 242.82 ± 128.02 µm to 42.12 ± 40.02 µm) compared to observed controls (from 251.22 ± 120.02 µm to 176.45 ± 98.09 µm) (p=0.003). A higher proportion of treated patients achieved complete resolution of subretinal fluid compared to observed controls (77.1% vs. 34.8%, = 0.034). However, change in mean visual acuity at 3 months was similar in both groups (p = 0.071). There was no significant change in intraocular pressure in either group (p= 0.216). Conclusion: Topical brinzolamide 1% had an improvement in function and anatomy in  the treatment of central serous chorioretinopathy. Topical brinzolamide 1% is a safe choice   for patients with central serous chorioretinopathy.